Skip to content

APRIL NEWS ROUND UP!

There have been some exciting recent developments in the ophthalmology and optical industry:
 
πŸ‘οΈ Gene Therapy has restored vision in a teen with Leber Congenital Amaurosis

In a ground-breaking clinical trial sponsored by Atsena Therapeutics, 16-year-old Aiden Van De Rostyne-Moore was given the gift of sight after years of blindness caused by Leber congenital amaurosis, thanks to an experimental gene therapy treatment which sends tiny molecular machinery to the retina at the back of the eye. The aim of the therapy is to provide a working form of a critical gene for vision.

πŸ‘οΈ Lumata Health and Prevent Blindness Join Forces for Vision Loss Support

Lumata Health and Prevent Blindness have announced a partnership to fight blindness and save sight. The organizations will collaborate on various initiatives aimed at overcoming care barriers for patients, with an initial emphasis on mental health resources.

πŸ‘οΈ Scientists achieve promising results towards restoring vision in blindness caused by cellular degeneration in the eye
 
Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.
 
A preclinical study using stem cells to produce progenitor photoreceptor cells -- light-detecting cells found in the eye -- and then transplanting these into experimental models of damaged retinas has resulted in significant vision recovery.

πŸ‘οΈ SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenses

SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children.

πŸ‘οΈ Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic System
 
Bausch + Lomb announced the US launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc Viscoelastic System. StableVisc and TotalVisc provide eye surgeons with new options for dual-action protection during cataract surgery.

Links: Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic System (eyewire.news), https://lnkd.in/e972r-q2https://lnkd.in/eqNu_iwN https://lnkd.in/ezQeZ4zb https://lnkd.in/dB_Ry2Pu